Sign In
Buy MRNS
$0.550
+0 (+0%)
At Close: May 09, 2025
Investors in Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
07:20am, Monday, 01'st Jul 2024
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securiti
Investors in Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
07:15am, Monday, 01'st Jul 2024
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securiti
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
05:45am, Monday, 01'st Jul 2024
NEW YORK , July 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action securities lawsuit. CLA
August 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MRNS
03:45pm, Sunday, 30'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
03:24pm, Sunday, 30'th Jun 2024
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ: MRN
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmace
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceu
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceu
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 5, 2024 in Marinus Pharmaceuticals, Inc. Lawsuit - MRNS
09:03pm, Saturday, 29'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 29, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) - August 5, 2024 Deadline to Join - Contact Levi & Korsinsky
09:01pm, Saturday, 29'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 29, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceu
